Promethera Biosciences partners with Shibu... Promethera Biosciences and Shibuya collaborate to establish a breakthrough cell therapy manufacturing platform. more ➔
Immatics raises $58m Cancer immunotherapy specialist Immatics Biotechnologies GmbH (Tuebingen, Germany) raised US$58m in a Series E financing round led by German investors dievini Hopp BioTech Holding and AT Impf as well … more ➔
NuCana raises US$114m in IPO of ADSsScotch cancer corp NuCana plc was up 3% (to US$18.61) after closing an initial public offering on Friday led by Citigroup, Jefferies and Cowen and co-managed by William Blair. more ➔
Researchers unravel patterns of cancer het...Up to recently, it was not possible for academic researchers to visualise the spatial distribution of intratumoural heterogeneity within solid tumours. An international research team has now reported … more ➔
Ablynx takes Phase III hurdle in acquired...Belgian nanobody developer Ablynx NV’s nanobody caplacizumab has met relevant endpoints in the pivotal Hercules Phase III study in patients with thrombotic thrombocytopenic purpura (aTTP), paving … more ➔
Dipstick test detects ZikaA newly-developed, fast, and cost-effective dipstick test sensitively and specifically identified Zika virus and all four dengue virus subtypes without any detectable cross-reactivity. more ➔
Why to watch out SpainThe Spanish biotech sector is growing. This attracts more and more international investors. End of September ASEBIO organised the first edition of an Investor Day. more ➔
Evotec acquires stake in Exscientia German CRO Evotec AG announced an €15m investment in British Exscienta Ltd. to push artificial intelligence (AI)-driven drug discovery. more ➔
Genmab bags €25m milestone upon market a...Danish Genmab A/S has received market approval in Japan for its anti-CD38 antibody daratumumab (DARZALEX®) as therapy for relapsed or refractory Multiple Myeloma. more ➔
Newron raises CHF27m Neurology specialist Newron Pharmaceuticals S.p.A. (Milan) has raised gross proceeds of CHF 27m through a private placement of new shares via an accelerated book-building process. more ➔
